The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in patients with type 2 diabetes and a wider range of CKD is unclear. METHODS: (stage 1 or 2 CKD). Patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary outcome, assessed in a time-to-event analysis, was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. The first secondary outcome was a composite of kidney failure, a sustained decrease from baseline of at least 40% in the eGFR, or death from renal causes. Safety was assessed as investigator-reported adverse events. RESULTS: A total of 7437 patients underwent randomization. Among the patients included in the analysis, during a median follow-up of 3.4 years, a primary outcome event occurred in 458 of 3686 patients (12.4%) in the finerenone group and in 519 of 3666 (14.2%) in the placebo group (hazard ratio, 0.87; 95% confidence interval [CI], 0.76 to 0.98; P = 0.03), with the benefit driven primarily by a lower incidence of hospitalization for heart failure (hazard ratio, 0.71; 95% CI, 0.56 to 0.90). The secondary composite outcome occurred in 350 patients (9.5%) in the finerenone group and in 395 (10.8%) in the placebo group (hazard ratio, 0.87; 95% CI, 0.76 to 1.01). The overall frequency of adverse events did not differ substantially between groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone (1.2%) than with placebo (0.4%). CONCLUSIONS: Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, finerenone therapy improved cardiovascular outcomes as compared with placebo. (Funded by Bayer; FIGARO-DKD ClinicalTrials.gov number, NCT02545049.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in kidney failure: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with diabetic kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors,3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors,6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone8,9 all reduced the risk of progression to kidney failure.”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) outcome trial (460) demonstrates a significant relationship between reduction in moderately increased albuminuria and reduction in cardiovascular risk.”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [460]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Discontinuation of trial regimen was higher among those on fi nerenone than placebo (1.2% vs. 0.4%).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with T2D and albuminuria are known to be at high risk of CKD progression and cardiovascular events, and the FIDELIO-DKD and FIGARO-DKD trials demonstrated that fi nerenone reduced these events (particularly CKD progression and heart failure) among such patients.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pooled analysis of two complementary trials comprising 13 026 patients with a broad spectrum of CKD and type 2 diabetes, all treated with an optimized dose of an ACEi or ARB,7 , 10 provides robust evidence of both cardiovascular and kidney protection with finerenone vs. placebo.”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People with type 2 diabetes and CKD should be considered for treatment with finerenone to reduce cardiovascular outcomes and the risk of CKD progression (239–242).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finerenone was investigated in two complementary phase 3 studies of patients with T2D, kidney disease (defined primarily as ACR ≥30 mg/g), and potassium <4.8 mmol/L and is the only ns-MRA approved in the world for slowing CKD progression and reducing cardiovascular events.”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in ESKD: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“There was a 13% lower risk of the primary cardiovascular composite outcome, which included death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“The secondary composite kidney outcome, which included kidney failure, sustained decrease from baseline of at least 40% in eGFR, or death from kidney causes, was not signi fi cantly different between fi nerenone and placebo (HR 0.87, 95% CI 0.76 -1.01).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“On average, there was only a small reduction in systolic blood pressure (3 mm Hg) with fi nerenone compared to placebo, and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“and fi nerenone reduced the risk of kidney and cardiovascular outcomes in 2 pivotal outcome trials.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the primary cardiovascular composite outcome risk in a broader patient population than studied in FIDELIO-DKD (patients with stage 2–4 CKD and moderately increased albuminuria, or stage 1–2 CKD with severely increased albuminuria).7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The FIDELIO-DKD trial was designed to detect a treatment effect of finerenone on kidney failure endpoints, whereas the FIGARO-DKD trial aimed to detect an effect on a cardiovascular composite primary endpoint.7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76-0.98];P = 0.03) in people with type 2 diabetes and CKD (248).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56-0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56–0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76–0.98]; P = 0.03) in people with type 2 diabetes and CKD (240).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In summary, FIDELIO-DKD and FIGARO-DKD demonstrated cardiovascular and kidney benefits for finerenone among people with T2D who were treated with standard of care (including an RAS inhibitor at maximally tolerated doses and good control of glycemia and BP) who were at high residual risk, based largely on albuminuria (ACR ≥30 mg/g).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Physical activity and aerobic exercise guidelines are similar in persons with T2D independent of lean vs overweight/obese BMI.431,674,727,728”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [431]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overall, the updated evidence review identifi ed 27 RCTs on MRA, with 5 RCTs comparing nonsteroidal MRA to placebo and/or standard of care.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredIn the citing paper
“According to two large randomized placebo-controlled trials targeted at T2DM and CKD patients, finerenone has been demonstrated to significantly reduce the occurrences of composite renal outcome”
In the citing paper
“and composite cardiovascular outcome (defined as a composite of nonfatal MI, nonfatal stroke, death from cardiovascular causes, or hospitalization for heart failure [HHF]), regardless of patients with or without established cardiovascular disease [16, 17].”
In the citing paper
“Even more recently, the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone has been shown to confer both cardiovascular and kidney protection in patients with T2D and CKD, in both a dedicated kidney outcome trial and a dedicated cardiovascular outcome trial [22,23].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [23]
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the composite cardiovascular outcome, which was the primary outcome of the trial (HR: 0.87, 95% CI: 0.76-0.98).26”
In the citing paper
“FIDELIO-DKD and FIGARO-DKD each enrolled people with T2D treated with the maximum-tolerated dose of RASi who had residual albuminuria (ACR $30 mg/g [$3 mg/mmol]) and a nonelevated serum potassium (<4.8 mEq/l at screening).”
In the citing paper
“This recommendation is based on the high-quality evidence from FIDELIO-DKD and FIGARO-DKD (Grade A, summarized above) that finerenone slows progression of CKD and reduces risks of cardiovascular events in this population.25,26”
In the citing paper
“Two large clinical trials (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease [FIDELIO-DKD] 25 and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease [FIGARO-DKD] 26 ) and a pre-specified individual-level combined analysis of these 2 trials (The FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD”
In the citing paper
“To mitigate hyperkalemia risk, the FIDELIO-DKD and FIGARO-DKD trials restricted eligibility to patients with non-elevated serum potassium concentration (after maximizing RASi) and implemented a standardized potassiummonitoring protocol.”
In the citing paper
“The HR of the primary outcome of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization from heart failure was reduced by 13% in patients treated with fi nerenone.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationChronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
Self-citationMcGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citationCoresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review
Mima, A., Nomura, A., & Yasuzawa, T. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2521086 · Cited by 27
Nonsteroidal and Steroidal Mineralocorticoid Antagonists
Harrington, J., Canonico, M. E., Rafei, A. E., Solomon, S. D., Teerlink, J. R., Vaduganathan, M., Zieroth, S. R., Bonaca, M. P., & Sauer, A. J. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102637 · Cited by 27
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 29
Hallström, S., Wijkman, M. O., Ludvigsson, J., Ekman, P., Pfeffer, M. A., Wedel, H., Rosengren, A., & Lind, M. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100469 · Cited by 30
Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes
Kamalumpundi, V., Shams, E., Tucker, C., Cheng, L., Peterson, J., Thangavel, S., Ofori, O., & Correia, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115304 · Cited by 27
2023 Clinical Practice Guidelines for Diabetes
Moon, M. K. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.120 · Cited by 27
The renin-angiotensin-aldosterone system: An old tree sprouts new shoots
Ruan, Y., Yu, Y., Wu, M., Jiang, Y., Qiu, Y., & Ruan, S. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111426 · Cited by 26
Grams, M. E., & Melamed, M. L. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02684 · Cited by 27
Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies
Lv, Y., Ye, C., Li, Z., Ye, J., Cao, H., Zhang, C., Jiang, H., & Wang, Y. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70098 · Cited by 27
Ortíz, A., Wanner, C., Gansevoort, R. T., Ortíz, A., Wanner, C., Gansevoort, R. T., Cozzolino, M. G., Fliser, D., Gambaro, G., Ong, A. C. M., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac199 · Cited by 26
Jo, R., Shibata, H., Kurihara, I., Yokota, K., Kobayashi, S., Murai‐Takeda, A., Mitsuishi, Y., Hayashi, T., Nakamura, T., & Itoh, H. (2022) · Hypertension Research · doi:10.1038/s41440-022-01036-6 · Cited by 28
Kofod, D. H., Carlson, N., Ballegaard, E. L. F., Almdal, T., Torp-Pedersen, C. T., Gislason, G., Svendsen, J. H., Feldt‐Rasmussen, B., & Hornum, M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01867-8 · Cited by 27
Aldosterone: Essential for Life but Damaging to the Vascular Endothelium
Crompton, M., Skinner, L. J., Satchell, S. C., & Butler, M. J. (2023) · Biomolecules · doi:10.3390/biom13061004 · Cited by 26
Triposkiadis, F. K., Sarafidis, P. A., Briasoulis, Α., Magouliotis, D. E., Athanasiou, T., Skoularigis, J. S., & Xanthopoulos, A. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155090 · Cited by 27
Mottl, A. K., & Nicholas, S. B. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.09.003 · Cited by 27
Tanaka, T., Maruyama, S., Chishima, N., Akiyama, H., Shimamoto, K., Inokuchi, S., Yokota, K., & Ozaki, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-55827-7 · Cited by 26
Novel pharmacological approaches to lowering blood pressure and managing hypertension
Sayer, M., Webb, D. J., & Dhaun, N. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01131-4 · Cited by 26
Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention
Akam, E. Y., Nuako, A. A., Daniel, A. K., & Stanford, F. C. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01451-6 · Cited by 26
Emerging drugs for the treatment of diabetic nephropathy
Kim, Y. K., Ning, X., Munir, K. M., & Davis, S. N. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2155632 · Cited by 25
Fujii, W., & Shibata, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097719 · Cited by 25
Albakr, R. B., Sridhar, V. S., & Cherney, D. Z. I. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.04.015 · Cited by 25
Daprodustat and Heart Failure in CKD
Cunningham, J. W., Claggett, B. L., Lópes, R. D., McMurray, J. J. V., Perkovic, V., Carroll, K., Hiemstra, T. F., Khavandi, K., Lukas, M. A., Ranganathan, P. R., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000321 · Cited by 24
Schaefer, F. S., Montini, G., Kang, H. G., Walle, J. V., Zaritsky, J. J., Schreuder, M. F., Litwin, M., Scalise, A. V., Scott, H., Potts, J., et al. (2024) · Trials · doi:10.1186/s13063-024-08021-z · Cited by 24
Nardoianni, G., Pala, B., Scoccia, A., Volpe, M., Barbato, E., & Tocci, G. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00634-4 · Cited by 25
Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism
Marcelli, M., Bi, C., Funder, J. W., & McPhaul, M. J. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22884 · Cited by 24
The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Russo, V., Vetrano, E., et al. (2024) · Biomolecules · doi:10.3390/biom14111393 · Cited by 25
Fernando, K., Connolly, D. L., Darcy, E., Evans, M., Hinchliffe, W., Holmes, P., & Strain, W. D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01738-3 · Cited by 25
Pyne, L., Rossignol, P., Giles, C., Junek, M., Mark, P. B., Gallagher, M., de Zoysa, J., Devereaux, P. J., & Walsh, M. W. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01153-5 · Cited by 24
Sex and Gender Related Differences in Diabetic Kidney Disease
Sridhar, V. S., Yau, K., Benham, J. L., Campbell, D. J. T., & Cherney, D. Z. I. (2022) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2022.04.007 · Cited by 23
Georgianos, P. I., Vaios, V., Koufakis, T., & Liakopoulos, V. (2024) · Drugs · doi:10.1007/s40265-024-02091-8 · Cited by 24
Rashid, A. M., Khan, M. S., Cherney, D. Z. I., Mehta, A. N., Rangaswami, J., Shafi, T., & Butler, J. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000752 · Cited by 23
Ghafoury, R., Malek, M., Ismail‐Beigi, F., & Khamseh, M. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01743-6 · Cited by 24
Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management
Chen, D., Sindone, A. P., Huang, M., Peter, K., & Jenkins, A. J. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.06.013 · Cited by 25
Rossing, P. R. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.005 · Cited by 24
Self-citationAmerican Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-ad08a · Cited by 25
Clinical implications and guidelines for CKD in type 2 diabetes
Zhang, R. M., Persson, F., McGill, J. B., & Rossing, P. R. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac285 · Cited by 25
Self-citationTherapeutic Advances in Diabetic Kidney Disease
Georgianos, P. I., Vaios, V., Eleftheriadis, T., Papachristou, E. C., & Liakopoulos, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032803 · Cited by 23
Chen, W., Zheng, L., Wang, J., Lin, Y., & Zhou, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1320603 · Cited by 23
Additive renal protective effects between arctigenin and puerarin in diabetic kidney disease
Li, X., Wang, J., Yan, J., He, C., Li, Y., & Zhong, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116107 · Cited by 23
Nicholas, S. B., Correa‐Rotter, R., Desai, N. R., Guo, L., Navaneethan, S. D., Pantalone, K. M., Wanner, C., Hamacher, S., Fatoba, S., Horvat-Broecker, A., et al. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02070-y · Cited by 24
Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India
Jain, P., Guha, S., Kumar, S., Sawhney, J. P. S., Sharma, K. H., Sureshkumar, K. P., Mehta, A., Dhediya, R., Gaurav, K., Mittal, R., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00367-4 · Cited by 24
Distinct Comorbidity Clusters in Patients With Acute Heart Failure
Gomez, K. F. A., Tromp, J., Figarska, S. M., Beldhuis, I. E., Cotter, G., Davison, B. A., Felker, G. M., Gimpelewicz, C. R., Greenberg, B., Lam, C. S. P., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.028 · Cited by 22
Navaneethan, S. D., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Ruilope, L. M., August, P., BRINKER, M. D., Lage, A. Z., Roberts, L., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.03.018 · Cited by 22
Self-citationRossing, P. R., Bakris, G. L., Perkovic, V., Pratley, R. E., Tuttle, K. R., Mahaffey, K. W., Idorn, T., Belmar, N., Bosch‐Traberg, H., Rasmussen, S., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0472 · Cited by 22
Self-citationNext-generation therapeutics for diabetic kidney disease
Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 24
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 28
Potassium management with finerenone: Practical aspects
Wanner, C., Fioretto, P., Kovesdy, C. P., Małyszko, J., Pecoits‐Filho, R., Schnell, O., & Rossignol, P. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.360 · Cited by 23
Chronic kidney disease after lung transplantation in a changing era
Grootjans, H., Verschuuren, E. A. M., van Gemert, J. P., Kerstjens, H. A. M., Bakker, S. J. L., Berger, S. P., & Gan, C. T. (2022) · Transplantation Reviews · doi:10.1016/j.trre.2022.100727 · Cited by 22
Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
Oiwa, A., Hiwatashi, D., Takeda, T., Miyamoto, T., Kawata, I., Koinuma, M., Yamazaki, M., & Komatsu, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad144 · Cited by 22
The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes
Kearney, J., & Gnudi, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051343 · Cited by 22
Tuttle, K. R., Rossing, P. R., Hauske, S. J., Cronin, L., Hussain, J., de Zeeuw, D., & Heerspink, H. J. L. (2023) · American Journal of Nephrology · doi:10.1159/000534808 · Cited by 22
Self-citationEquity and Quality of Global Chronic Kidney Disease Care: What Are We Waiting for?
Luyckx, V. A., Elmaghrabi, A., Sahay, M., Scholes-Robertson, N. J., Solá, L., Speare, T., Tannor, E. K., Tuttle, K. R., & Okpechi, I. G. (2023) · American Journal of Nephrology · doi:10.1159/000535864 · Cited by 24
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02250-2 · Cited by 22
Exploring molecular targets in diabetic kidney disease
Maruno, S., Tanaka, T., & Nangaku, M. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.251 · Cited by 22
Sarafidis, P. A., Pella, E., Kanbay, M., & Papagianni, A. A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220825121304 · Cited by 21
Novel strategies in nephrology: what to expect from the future?
Çöpür, S., Tanrıöver, C., Yavuz, F., Soler, M. J., Ortíz, A., Covic, A. C., & Kanbay, M. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac212 · Cited by 22
Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
Gregg, L. P., & Navaneethan, S. D. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac284 · Cited by 21
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022
Orozco‐Beltrán, D., Cuixart, C. B., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Rioboó, E. M., Baldó, A. J., Vicuña, J., & Pérez, J. N. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102444 · Cited by 64
Chen, Q., Liang, Y., Yan, J., Du, Y., Li, M., Chen, Z., & Zhou, J. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110210 · Cited by 21
Renal Mechanisms of Diuretic Resistance in Congestive Heart Failure
Lameire, N. H. (2023) · Kidney and Dialysis · doi:10.3390/kidneydial3010005 · Cited by 21
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 21
Morales, J., Dagogo-Jack, S. E., Fonseca, V. A., Neumiller, J. J., & Rosas, S. E. (2023) · Clinical Diabetes · doi:10.2337/cd22-0110 · Cited by 21
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 22
Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation
Azzam, O., Nejad, S. H., Carnagarin, R., Nolde, J. M., Kiuchi, M. G., & Schlaich, M. P. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16247 · Cited by 21
The current best drug treatment for hypertensive heart failure with preserved ejection fraction
Rist, A., Sevre, K., Wachtell, K., Devereux, R. B., Aurigemma, G. P., Smiseth, O. A., Kjeldsen, S. E., Julius, S., Pitt, B., Burnier, M., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.008 · Cited by 23
Self-citationZhang, H., Xie, J., Hao, C., Li, X., Zhu, D., Zheng, H., Xu, X., Mo, Z., Lu, W., Lu, Y., et al. (2023) · Kidney Diseases · doi:10.1159/000531997 · Cited by 20
Perakakis, N., Bornstein, S. R., Birkenfeld, A. L., Linkermann, A., Demir, M., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Ruilope, L. M., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15305 · Cited by 20
Self-citationGawryś, O., Kala, P., Sadowski, J., Melenovský, V., Sandner, P., & Červenka, L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177175 · Cited by 20
Zannad, F. M., McGuire, D. K., & Ortíz, A. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20050 · Cited by 20
Shetty, S., Suvarna, R., Awasthi, A., Bhojaraja, M. V., & Pappachan, J. M. (2025) · Diagnostics · doi:10.3390/diagnostics15080973 · Cited by 22
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 21
Aging at the Crossroads of Organ Interactions: Implications for the Heart
Sen, I., Trzaskalski, N. A., Hsiao, Y., Liu, P. P., Shimizu, I., & Dérumeaux, G. (2025) · Circulation Research · doi:10.1161/circresaha.125.325637 · Cited by 20
Kobayashi, M., Bayés‐Genís, A., Duarte, K., McMurray, J. J. V., Ferreira, J. P., Pocock, S., van Veldhuisen, D. J., Lupón, J., Pitt, B., Zannad, F. M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf457 · Cited by 20
Self-citationLala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.06.013 · Cited by 23
Neuen, B. L., Heerspink, H. J. L., Perkovic, V., Cherney, D. Z. I., Lam, C. S. P., Tuttle, K. R., Wanner, C., Sarafidis, P. A., Anker, S. D., Filippatos, G. S., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01009-3 · Cited by 20
Self-citationUpdate on Hypertension Research in 2021
Mogi, M., Maruhashi, T., Higashi, Y., Masuda, T., Nagata, D., Nagai, M., Bokuda, K., Ichihara, A., Nozato, Y., Toba, A., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-00967-4 · Cited by 21
Rodríguez‐Espinosa, D., Guzmán-Bofarull, J., Fuente-Mancera, J. C. D. L., Maduell, F., Broseta, J. J., & Farrero, M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.913580 · Cited by 20
Wish, J. B., & Pérgola, P. E. (2022) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2022.09.002 · Cited by 20
Rossing, P. R., Garweg, J. G., Anker, S. D., Osonoi, T., Pitt, B., Rosas, S. E., Ruilope, L. M., Zhu, D., BRINKER, M. D., Finis, D., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14915 · Cited by 20
Self-citationNgoc, N. B., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15009 · Cited by 21
Masuda, T., & Nagata, D. (2023) · Hypertension Research · doi:10.1038/s41440-023-01220-2 · Cited by 20
Schechter, M., Cohen, C. M., Fishkin, A., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Chodick, G., Clark, A., Abrahamsen, T. J., Lawson, J., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01829-0 · Cited by 23
Ashjian, E. J., Clarke, M. M., & Pogue, K. T. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad192 · Cited by 20
Albuminuria in Transthyretin Cardiac Amyloidosis: Prevalence, Progression and Prognostic Importance
Ioannou, A., Rauf, M. U., Patel, R. K., Razvi, Y., Porcari, A., Martinez–Naharro, A., Venneri, L., Bandera, F., Virsinskaite, R., Kotecha, T., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3094 · Cited by 20
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02053-6 · Cited by 20
Resistant hypertension: Diagnosis, evaluation, and treatment practical approach
Parodi, R., Brandani, L., Romero, C. R., & Klein, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.12.026 · Cited by 20
van den Berg, P., Ruppert, M., Mešić, E., Snelder, N., Seelmann, A., Heinig, R., Joseph, A., Garmann, D., Lippert, J., & Eißing, T. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01082-2 · Cited by 20
Self-citationEpstein, M. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.008 · Cited by 20
Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers
Borrelli, S., Matarazzo, I., Lembo, E., Peccarino, L., Annoiato, C., Scognamiglio, M., Foderini, A., Ruotolo, C., Franculli, A., Capozzi, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126378 · Cited by 22
Zhou, J., Kang, L., Gu, C., Li, X., Guo, X., & Fang, M. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2400541 · Cited by 20
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101069 · Cited by 20
Ktenopoulos, N., Anagnostopoulou, L., Apostolos, A., Iliakis, P., Karakasis, P., Milaras, N., Theofilis, P., Fragoulis, C., Drakopoulou, M., Synetos, A. G., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47110886 · Cited by 19
Matsumoto, Y., Orihara, Y., Asakura, M., Min, K.-D., Okuhara, Y., Azuma, K., Nishimura, K., Sunayama, I., Kashiwase, K., Naito, Y., et al. (2022) · Heart and Vessels · doi:10.1007/s00380-022-02025-y · Cited by 19
Donate‐Correa, J., Sánchez-Niño, M. D., González-Luis, A., Ferri, C. M., Martín-Olivera, A., Martín‐Núñez, E., Fernández‐Fernández, B., Tagua, V. G., Fernández, C. M., Ortíz, A., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac143 · Cited by 19
Marzolla, V., Infante, M., Armani, A., Rizzo, M., & Caprio, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2130889 · Cited by 19
Sawami, K., Tanaka, A., & Node, K. (2023) · Hypertension Research · doi:10.1038/s41440-023-01324-9 · Cited by 19
Borg, R., Kriegbaum, M., Grand, M. K., Lind, B., Andersen, C. L., & Persson, F. (2023) · BMC Family Practice · doi:10.1186/s12875-023-02077-7 · Cited by 19
Herzinsuffizienz: Leitlinien-Update der ESC 2023
Bauersachs, J. K., & Soltani, S. (2023) · Herz · doi:10.1007/s00059-023-05221-2 · Cited by 19
Diabetic Kidney Disease Prevention Care Model Development
ElSayed, N. A., Bannuru, R. R., Bakris, G. L., Bardsley, J. K., de Boer, I. H., Gabbay, R. A., Gockerman, J. P., McCoy, R. G., McCracken, E., Neumiller, J. J., et al. (2023) · Clinical Diabetes · doi:10.2337/cd23-0063 · Cited by 22
Self-citationZhou, L. N., & Li, W. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04142-1 · Cited by 19
Metadata
- Authors
- Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-09
- Volume
- 385
- Issue
- 24
- Pages
- 2252-2263
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3194763937
- Cited by
- 1,814
- References
- 32
- Citations by year
- 2026: 439 · 2025: 435 · 2024: 331 · 2023: 315 · 2022: 250 · 2021: 41
- FWCI
- 160.23
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- National University of Singapore (submittedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Bayer (ClinicalTrials.gov NCT02545049)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- mineralocorticoid receptor antagonists, type 2 diabetes, chronic kidney disease, cardiovascular events, heart failure hospitalization, albuminuria, renin-angiotensin system blockade, hyperkalemia, estimated glomerular filtration rate decline, renal failure, cardiorenal outcomes, FIDELIO-DKD
- MeSH terms
- Aged, Albuminuria, Mineralocorticoid Receptor Antagonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Proportional Hazards Models, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
